Market Place
Sourcing Support
Iovance Awards Employee Inducements Under Nasdaq Rule 5635(c)(4)
20 Mar 2026 //
GLOBENEWSWIRE
Iovance Showcases Strong Q4 and Full-Year 2025 Results
24 Feb 2026 //
GLOBENEWSWIRE
Real-World Data Backs Early Amtagvi Use For Advanced Melanoma
05 Feb 2026 //
GLOBENEWSWIRE
Iovance Grants Inducements Under Nasdaq Rules LR 5635(C)(4)
16 Jan 2026 //
GLOBENEWSWIRE
Iovance Biotherapeutics Discloses Inducement Grants Per Nasdaq
19 Dec 2025 //
GLOBENEWSWIRE
Iovance Biotherapeutics Discloses Inducement Grants Per NASDAQ
21 Nov 2025 //
GLOBENEWSWIRE
Iovance Bio To Host Q3 2025 Financial Results & Webcast
23 Oct 2025 //
GLOBENEWSWIRE
Iovance Biotherapeutics Discloses Inducement Grants Per Nasdaq
17 Oct 2025 //
GLOBENEWSWIRE
Iovance Bio Reports Inducement Grants under Nasdaq LR 5635(c)(4)
19 Sep 2025 //
GLOBENEWSWIRE
Iovance Biotherapeutics to Present at Upcoming Conferences
29 Aug 2025 //
GLOBENEWSWIRE
Iovance Announces Inducement Grants Under NASDAQ Rule 5635(c)(4)
22 Aug 2025 //
GLOBENEWSWIRE
Iovance`s Amtagvi approved by Health Canada for advanced Melanoma
18 Aug 2025 //
GLOBENEWSWIRE
Iovance Biotherapeutics Reports Q2 and First-Half 2025 Results
07 Aug 2025 //
GLOBENEWSWIRE
Iovance Biotherapeutics issues Inducement Grants per NASDAQ Rule
18 Jul 2025 //
GLOBENEWSWIRE
Iovance Biotherapeutics Names Marc R. Theoret, M.D. Senior VP
10 Jul 2025 //
GLOBENEWSWIRE
Iovance Biotherapeutics to Present at Upcoming Conference
10 Jun 2025 //
GLOBENEWSWIRE
Iovance reveals 5-year Amtagvi results in Advanced melanoma
22 May 2025 //
GLOBENEWSWIRE
Iovance Bio Reports Inducement Grants under Nasdaq LR 5635(c)(4)
16 May 2025 //
GLOBENEWSWIRE
Iovance Biotherapeutics Q1 2025 Financial Results Webcast May 8
02 May 2025 //
GLOBENEWSWIRE
Iovance Biotherapeutics to Participate in Scientific Congresses
23 Apr 2025 //
GLOBENEWSWIRE
Iovance Biotherapeutics Reports Q4 and Full Year 2024 Results
27 Feb 2025 //
GLOBENEWSWIRE
Iovance Bio Reports Inducement Grants under NASDAQ LR 5635(c)(4)
12 Feb 2025 //
GLOBENEWSWIRE
Iovance Biotherapeutics Appoints Dan as Chief Commercial Officer
10 Feb 2025 //
GLOBENEWSWIRE
Iovance Bio Reports Inducement Grants under NASDAQ LR 5635(c)(4)
17 Jan 2025 //
GLOBENEWSWIRE
Iovance Bio Reports Inducement Grants under NASDAQ LR 5635(c)(4)
20 Dec 2024 //
GLOBENEWSWIRE
Iovance Biotherapeutic Promotes Raj Puri to Chief Regulatory Officer
26 Nov 2024 //
GLOBENEWSWIRE
Iovance Biotherapeutics Q3 & YTD 2024 Results & Updates
07 Nov 2024 //
GLOBENEWSWIRE
Iovance Biotherapeutics to Host Q3 & YTD 2024 Results Call on Nov 7
31 Oct 2024 //
GLOBENEWSWIRE
Iovance Biotherapeutics to Present at Upcoming Conferences
03 Sep 2024 //
GLOBENEWSWIRE
Iovance Biotherapeutics Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
16 Aug 2024 //
GLOBENEWSWIRE
Iovance Reports Q2 And H1 2024 Results And Updates
08 Aug 2024 //
GLOBENEWSWIRE
Iovance Submits Marketing Application To EMA For Lifileucel In Advanced Melanoma
28 Jun 2024 //
GLOBENEWSWIRE
BMS` triplet, Iovance`s Amtagvi-Keytruda target melanoma
24 May 2024 //
FIERCE PHARMA
Iovance Frontline Melanoma Data: To Be Presented At Asco 2024
23 May 2024 //
GLOBENEWSWIRE
US FDA grants accelerated approval for Iovance`s skin cancer cell therapy
17 Feb 2024 //
REUTERS
Iovance Biotherapeutics Reports Third Quarter Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
Iovance Bio Reports Second Quarter and First Half 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
Iovance Announces U.S. FDA Acceptance of the BLA of Lifileucel
26 May 2023 //
GLOBENEWSWIRE
Iovance Completes BLA Submission for Lifileucel in Advanced Melanoma
24 Mar 2023 //
GLOBENEWSWIRE
